Redirected HBV-Specific T Cells in Patients With HBV-related HCC (SAFE-T-HBV)

Cannot have received: immune checkpoint inhibitor

Use of immune checkpoint inhibitors and/or tyrosine kinase inhibitor (TKI) within 5 half-lives of the drug prior to baseline liver biopsy procedure

Cannot have received: tyrosine kinase inhibitor

Use of immune checkpoint inhibitors and/or tyrosine kinase inhibitor (TKI) within 5 half-lives of the drug prior to baseline liver biopsy procedure

Cannot have received: RFA/TACE

Last RFA/TACE treatment within 3 months prior to first LioCyx-M infusion

Cannot have received: Y90 therapy

Last Y90 therapy treatment within 6 months prior to first dose of mRNA HBV/TCR T-cells

Cannot have received: cytotoxic chemotherapy

Concurrent administration of any other anti-tumour therapy, including cytotoxic chemotherapy, hormonal therapy, and immunotherapy.

Cannot have received: hormonal therapy

Concurrent administration of any other anti-tumour therapy, including cytotoxic chemotherapy, hormonal therapy, and immunotherapy.

Cannot have received: immunotherapy

Concurrent administration of any other anti-tumour therapy, including cytotoxic chemotherapy, hormonal therapy, and immunotherapy.

Cannot have received: investigational product

Use of any investigational product (IP) or investigational medical device within 30 days of study drug administration